Opening windows for ten minutes every hour will help reduce the risk of catching the coronavirus indoors, people in England are being told in a public information campaign launching today. Penny Ward at King’s College London said in a statement that the government may want to assess its effectiveness in people who are vaccinated, as the trials so far have been in unvaccinated people. “We are working at pace to deploy molnupiravir to patients through a national study as soon as possible,” Health and Social Care Secretary Sajid Javid said in a statement. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised its use for people with at least one risk factor for severe infection, including being 60 or older, having diabetes, heart disease or obesity. It works by causing mutations as the virus duplicates its genetic material, stopping it from multiplying within cells. Molnupiravir should be taken as soon as possible after a positive covid-19 test, or at least within five days. Trials showed it halves the risk of people needing hospital treatment or dying. This medicine is also given twice daily to people who are at risk of severe illness but have not been hospitalised. Meanwhile, another antiviral called molnupiravir was approved yesterday in the UK. The results have not yet been fully published, but were announced today in a press release from Pfizer. The equivalent figures were 1 and 6.7 per cent for those who got treatment within five days. In a placebo-controlled trial of 1219 people from all over the world, 0.8 per cent of people who received Paxlovid within three days of a positive covid-19 test required hospital treatment, compared with 7 per cent of people who received a placebo. The second drug is called ritonavir developed as a treatment for HIV, it helps slow the breakdown of PF-07321332. Paxlovid, made by US firm Pfizer, is a combination of two drugs a compound currently called PF-07321332, which blocks activity of an enzyme that the coronavirus needs to replicate.
0 kommentar(er)
